To obtain postmarket safety and efficacy data on Boston Scientific LithoVue™ Elite System.
LithoVue Elite Registry is a post-market, multi-center, open label, non-randomized, prospective study to document the safety and efficacy data on Boston Scientific LithoVue™ Elite System. LithoVue Elite System, includes the StoneSmart™ Connect Console (reusable capital/workstation) and a single-use, disposable ureteroscope device. The LithoVue Elite System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract. This is a post-market registry study. Any subject who meets eligibility criteria, intends to undergo a diagnostic and/or therapeutic procedure utilizing the LithoVue Elite System, and is willing to provide written informed consent, will be approached and considered for enrollment in the study. Data from diagnostic/therapeutic ureteroscopy procedure and standard of care post-ureteroscopy follow-up visits will be collected. These standard of care follow-up visits are expected to be scheduled within 120 days of the ureteroscopic procedure.
Study Type
OBSERVATIONAL
The LithoVue Elite System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.
Occurrence of Serious Adverse Device Effects - Primary Safety Endpoint
Primary safety end point is the occurrence of Serious Adverse Device Effects (SADE) related to the LithoVue Elite System including, but not limited to urinary tract perforation and ureteral avulsion
Time frame: Up to 120 days of follow up
Technical Success using LithoVue Elite System - Primary Effectiveness Endpoint
Primary effectiveness endpoint is the technical success using LithoVue Elite System, defined as: * Scope allows access to intended urinary anatomy (including utilization of active deflection and guidewire or access sheath) * Scope allows diagnostic and therapeutic tools, as identified in product labelling, to be utilized at target area, if applicable * Scope provides sufficient imaging for target visualization, (stone, calyx, etc.) * Scope provides real-time urinary system pressure measurements at target sites, if applicable Tool used will be a yes or no question on the case report form
Time frame: Procedure
Occurrence of Procedure-Related Adverse Events and/or Adverse Device Effects Related to the LithoVue Elite System - Secondary Safety Endpoint
Secondary safety endpoint is the occurrence of Procedure-related adverse events and/or adverse device effects related to the LithoVue Elite System
Time frame: Up to 120 days of follow up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.